Indication · Crohn's Disease

Crohn's Disease FDA approvals, PDUFA dates and pipeline.

Updated Snapshot 20261116T222116ZBuilt

We track 19 Crohn's Disease drugs. No FDA approvals recorded yet.

Drugs

Upcoming catalysts

DateDrugCompanyEventIndicationStatusSource
Aug to Nov 2026Quarter disclosedAZD7798AZNTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Dec 2026 to Mar 2027Quarter disclosedbrivekimig (SAR442970)SNYTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
December 2026Month disclosedbrivekimig (SAR442970)SNYPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Feb to May 2027Quarter disclosedzasocitinib (TAK-279)TAKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
February 2027Month disclosedzasocitinib (TAK-279)TAKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
March 2027Month disclosedrisankizumab sc (ABBV-066)ABBVPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Mar to Jun 2027Quarter disclosedrisankizumab sc (ABBV-066)ABBVTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Jun to Sep 2027Quarter disclosedTremfya (guselkumab)JNJTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Jun to Sep 2027Quarter disclosedEntyvio® (vedolizumab)TAKTopline readoutCrohn's DiseaseScheduledsec_424b
June 2027Month disclosedTremfya (guselkumab)JNJPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
June 2027Month disclosedEntyvio® (vedolizumab)TAKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
September 2027Month disclosedRINVOQ® (upadacitinib)ABBVPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Sep to Dec 2027Quarter disclosedRINVOQ® (upadacitinib)ABBVTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Oct 2027 to Jan 2028Quarter disclosedTremfya (guselkumab)JNJTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
October 2027Month disclosedTremfya (guselkumab)JNJPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
December 2027Month disclosedmirikizumab (LY3074828)LLYPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Dec 2027 to Mar 2028Quarter disclosedmirikizumab (LY3074828)LLYTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Mar to Jun 2028Quarter disclosedzasocitinib (TAK-279)TAKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
March 2028Month disclosedzasocitinib (TAK-279)TAKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
July 2028Month disclosedSL-325STTKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Jul to Oct 2028Quarter disclosedSL-325STTKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Oct 2028 to Jan 2029Quarter disclosediv tulisokibart (PRA023)MRKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
October 2028Month disclosediv tulisokibart (PRA023)MRKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
February 2029Month disclosedrisankizumab iv (ABBV-066)ABBVPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Feb to May 2029Quarter disclosedrisankizumab iv (ABBV-066)ABBVTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
April 2029Month disclosedSkyrizi® (risankizumab)ABBVPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Apr to Jul 2029Quarter disclosedSkyrizi® (risankizumab)ABBVTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
May to Aug 2029Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
May 2029Month disclosedduvakitug (TEV-48574)SNYPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Aug to Nov 2029Quarter disclosedduvakitug (TEV-48574)SNYTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
August 2029Month disclosedduvakitug (TEV-48574)SNYPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
January 2030Month disclosedABBV-8736ABBVPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov
Jan to Apr 2030Quarter disclosedABBV-8736ABBVTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
Mar to Jun 2030Quarter disclosedvedolizumab iv (MLN0002)TAKTopline readoutCrohn's DiseaseScheduledClinicalTrials.gov
March 2030Month disclosedvedolizumab iv (MLN0002)TAKPrimary completionCrohn's DiseaseScheduledClinicalTrials.gov

Past catalysts and decisions

DateDrugCompanyEventIndicationStatusSource
August 10, 2026AZD7798AZNPrimary completionCrohn's DiseaseCompletedClinicalTrials.gov
July 30, 2026SAR441566SNYPrimary completionCrohn's DiseaseWithdrawnClinicalTrials.gov
May 23, 2025Tremfya (guselkumab)JNJPrimary completionCrohn's DiseaseCompletedClinicalTrials.gov
Oct 2024Month disclosedobefazimod (ABX464)ABVXTrial startCrohn's diseaseCompletedsec_424b

All indications · Approval rates by indication

Questions

What Crohn's Disease drugs have upcoming PDUFA dates?

None disclosed.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.